Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
EDDC Granted FDA Fast Track for ADC EBC-129 to Treat Pancreatic Adenocarcinoma
Details : EBC-129 is a first-in-class ADC targeting a novel, tumour-specific N256-glycosylated epitope on CEACAM5 and CEACAM6 for treating pancreatic ductal carcinoma.
Product Name : EBC-129
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
May 28, 2025